Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease


A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease




The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.

Study Status: Completed


Condition Intervention Phase
Behcet Syndrome Drug: Apremilast (CC-10004)
Drug: Placebo
Phase 2

Verified by Celgene Corporation May, 2013

Sponsored by: Celgene Corporation
Information provided by: Celgene Corporation identifier: NCT00866359

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Yusuf Yazici, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site